Core 1: Systems Pathology Core

核心 1：系统病理学核心

• 批准号: 10629082
• 负责人: Anil V Parwani
• 金额: $ 26.9万
• 依托单位: CEDARS-SINAI MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-01 至 2028-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10629082
• 关键词: Address; Biological Assay; Cells; Cellular Indexing of Transcriptomes and Epitopes by Sequencing; Chromatin; Chromosomes; Clinical; Collection; Comparative Pathology; Consultations; Cooperative Human Tissue Network; Cytometry; Data; Data Analyses; Data Science Core; Detection; Diagnostic; Ensure; Epigenetic Process; Female; Flow Cytometry; Genomics; Goals; Gonadal Steroid Hormones; Histology; Human; Immune; Immunity; Immunofluorescence Immunologic; Immunohistochemistry; Immunologic Monitoring; Incidence; Institution; Malignant Neoplasms; Malignant neoplasm of urinary bladder; Manuscripts; Maps; Medical center; Molecular Analysis; Mus; Ohio; Outcome; Pathologic; Pathologist; Pathology; Process; Research; Research Personnel; Resource Sharing; Resources; Risk Factors; Role; Services; Sex Bias; Sex Chromosomes; Sex Differences; Signal Induction; Site; Smoking; Sorting; Specimen; System; Techniques; Translational Research; Transposase; Universities; Work; Writing; biobank; cancer cell; cancer risk; data integrity; data management; digital imaging; epigenomics; indexing; male; method development; neoplastic cell; pathology imaging; programs; sex; sex disparity; single cell analysis; single-cell RNA sequencing; therapy resistant; treatment response; tumor microenvironment; tumor progression

CORE 1, SYSTEMS PATHOLOGY – SUMMARY Sex differences in cancer risk, incidence, therapeutic response, and outcomes are well-known but poorly understood. Sex disparities relating to bladder cancers involves an interplay between sex chromosomes, sex hormones, and tumor micro-environment, including the immune cells and epigenomic alterations. The overarching goal of the Systems Pathology Core (Core 1) is to support Program investigators by providing streamlined and harmonized collection, processing and analysis of human and murine biospecimens to achieve the aims outlined in the Program projects. This core will be co-led by Dr. Anil Parwani (The Ohio State University Wexner Medical Center [OSUMC]) and Dr. Sergei Grivennikov (Cedars-Sinai Medical Center [CSMC]) and will provide coordinated services for this multi-institutional Program. To accomplish core goals and avoid duplication of services, Core 1 will work closely with resources at OSU, including the Comparative Pathology and Digital Imaging Shared Resource, the Pathology Department, the Immune Monitoring and Discovery Platform, and the Cooperative Human Tissue Network Midwestern network. At CSMC, Core 1 will utilize resources in the Flow Cytometry, Advanced Genomics, and Mass Cytometry Shared Resources as well as Biobank Translational Research Core. The specific aims and services for the Systems Pathology Core are: Specific Aim 1. Act as a high-quality biorepository to collect, process, bank, and distribute annotated human and murine bladder cancer specimens and their derivatives for Program research. Specific Aim 2. Provide histology and pathology services to analyze human and murine bladder cancer biospecimens using immunohistochemistry and immunofluorescence with pathological characterization and spatial mapping (via Co-Detection by Indexing [CODEX]). This core will also provide pathologist diagnostic consultation, project planning, method development, scoring, interpretation, and manuscript writing. Specific Aim 3. Provide flow cytometry and single cell analysis services including multiparameter flow cytometry analysis and sorting, single cell RNA sequencing (scRNAseq), Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITEseq), Assay for Transposase-Accessible Chromatin using sequencing (ATACseq), mass cytometry (CyTOF), and standard molecular analyses. The core will harmonize processing and analysis techniques across Program sites to ensure data integrity and unified results. The Systems Pathology Core will work closely with the Administrative Core and the Data Science Core, which will provide robust data management and analysis of the data acquired herein.

核心1，系统病理学-总结 癌症风险、发病率、治疗反应和结果的性别差异是众所周知的，但很少 明白与膀胱癌相关的性别差异涉及性染色体、性别 激素和肿瘤微环境，包括免疫细胞和表观基因组改变。的 系统病理学核心（核心1）的总体目标是通过提供以下服务来支持项目研究人员 简化和协调人和鼠生物标本的采集、处理和分析， 计划项目中列出的目标。该核心将由Anil Parwani博士（俄亥俄州州立大学）共同领导 Wexner Medical Center [OSUMC]）和Sergei Grivennikov博士（Cedars-Sinai Medical Center [CSMC]），并将 为这一多机构方案提供协调服务。实现核心目标，避免重复 核心1将与俄勒冈州立大学的资源密切合作，包括比较病理学和数字医学。 影像共享资源、病理科、免疫监测和发现平台以及 合作人体组织网络中西部网络。在CSMC，核心1将利用流程中的资源 细胞计数、先进基因组学和质谱细胞计数共享资源以及生物库翻译 研究核心。 系统病理学核心的具体目标和服务是： 具体目标1.作为一个高质量的生物储存库，收集、加工、储存和分发注释 人类和小鼠膀胱癌标本及其衍生物的项目研究。 具体目标2。提供组织学和病理学服务，分析人类和小鼠膀胱癌 使用免疫组织化学和免疫荧光技术对生物标本进行病理学表征， 空间映射（通过索引协同检测[CODEX]）。该核心还将提供病理学家诊断 咨询，项目规划，方法开发，评分，口译和手稿写作。 具体目标3。提供流式细胞仪和单细胞分析服务，包括多参数流式细胞仪 细胞计数分析和分选，单细胞RNA测序（scRNAseq），转录组的细胞索引 测序法（CITEseq），使用测序法测定转座酶可识别染色质 使用流式细胞仪（ATACseq）、质谱流式细胞术（CyTOF）和标准分子分析来检测。核心将协调处理 和分析技术，以确保数据的完整性和统一的结果。 系统病理学核心将与管理核心和数据科学核心密切合作， 其将提供稳健的数据管理和对在此获取的数据的分析。